A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

American Journal of Medicine

Volumn 115, Issue 1, 2003, Pages 41-46

  Klingbeil, Arnfried U ^a   Schneider, Markus ^a   Martus, Peter ^b   Messerli, Franz H ^c   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Ochsner for Children   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIVARIATE ANALYSIS OF COVARIANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0038642326     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00158-X     Document Type: Article

References (65)

1. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
2. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352.
3. Foley R.N., Parfrey P.S., Harnett J.D., et al. The prognostic importance of left ventricular geometry in the uremic cardiomyopathy. J Am Soc Nephrol. 5:1995;2024-2031.
4. Ghali J.K., Liao Y., Simmons B., et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 117:1992;831-836.
5. Muiesan M.L., Salvetti M., Rizzoni D., et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 13:1995;1091-1095.
6. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 97:1998;48-54.
7. Koren M.J., Ulin R.J., Koren A.T., et al. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 15:2002;1021-1028.
8. MacMahon S.W., Wilcken D.E.L., McDonald G.J. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N Engl J Med. 314:1986;334-339.
9. Jula A.M., Karanko H.M. Effects on left ventricular hypertrophy of long-term non-pharmacological treatment with sodium restriction in mild to moderate essential hypertension. Circulation. 89:1994;1023-1031.
10. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110.
11. Cruickshank J., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy of different types of antihypertensive therapy. J Hum Hypertens. 6:1992;85-90.
12. Liebson P.R., Grandits G.A., Dianzumba S., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment Of Mild Hypertension Study (TOMHS). Circulation. 91:1995;698-706.
13. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513.
14. Fagard R.H., Lijnen P.J. Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension. J Hypertens. 15:1997;309-317.
15. Agabiti-Rosei E., Zulli R., Muiesan M.L., et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Press. 7:1998;160-169.
16. Schobel H.P., Langenfeld M., Gatzka C.D., et al. Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J. 132:1996;1004-1009.
17. Chen C.H., Ting C.H., Lin S.J., et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 25:1995;1034-1041.
18. Gosse P., Gressin V., Clerson P., et al. Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function - a pilot study. Therapie. 54:1999;217-222.
19. Diamond J.A., Gharavi A., Roychoudhury D., et al. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Curr Med Res Opin. 13:1999;1-8.
20. Thürmann P.A., Kenedi P., Schmidt A., et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 98:1998;2037-2042.
21. Ofili E.O., Cohen J.D., St Vrain J.A., et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 279:1998;778-780.
22. Martina B., Dieterle T., Weinbacher M., Battegay E. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. Cardiology. 92:1999;110-114.
23. Kirpizidis H.G., Papazachariou G.S. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients a double-blind study. Cardiovasc Drugs Ther. 9:1995;141-143.
24. Höglund C., Cifkova R., Mimran A., et al. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology. 89:1998;263-270.
25. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens. 16:(7):1998;S23-S29.
26. Gonzalez-Juanatey J.R., Garcia-Acuna J.M., Calvo Gomez C., et al. Effect of verapamil and nitrendipine on left ventricular mass and function (systolic and diastolic) in arterial hypertension. Rev Esp Cardiol. 47:1994;375-383.
27. Topouchian J., Asmar R., Sayegh F., et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke. 30:1999;1056-1064.
28. Radevski I., Skudicky D., Candy G., et al. Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens. 12:1999;194-203.
29. Kan Y., Hong Z., Ming S. Effects of nitrendipine and captopril on the quality of life in hypertensives with left ventricular hypertrophy. Bull Hunan Med Univ. 20:1995;450-452.
30. Gottdiener J.S., Reda D.J., Massie B.M., et al. for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation. 95:1997;2007-2014.
31. Trenkwalder P., Dobrindt R., Aulehner R., Lydtin H. Antihypertensive treatment with felodipine but not with a diuretic reduces episodes of myocardial ischemia in elderly patients with hypertension. Eur Heart J. 15:1994;1673-1680.
32. Middlemost S.J., Tager R., Davis J., Sareli P. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol. 73:1994;1092-1097.
33. Himmelmann A., Svensson A., Dahlöf B., et al. Losartan in essential hypertension: effects on blood pressure and left ventricular mass. Blood Press. 4:1995;242-248.
34. Tedesco M.A., Ratti G., Aquino D., et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens. 12:1998;505-510.
35. Sadowski S., Szwed H., Kuch-Wocial A., et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine a double blind, randomized, controlled (versus nifedipine) study. J Hypertens. 16:1998;S55-S62.
36. Roman M.J., Alderman M.H., Pickering T.G., et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens. 11:1998;287-296.
37. Papademetriou V., Gottdiener J.S., Narayan P., et al. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. J Am Coll Cardiol. 30:1997;1802-1808.
38. Lacourciere Y., Poirier L., Cleroux J. Physical performance is preserved after regression of left ventricular hypertrophy. J Cardiovasc Pharmacol. 30:1997;383-391.
39. Henderson R.J., Cranswick R.W., Hunyor S.N. Structural adaptation of the heart in borderline hypertensives in response to blood pressure lowering with captopril. J Hypertens. 12:1994;65-72.
40. Cuspidi C., Lonati L., Sampieri L., et al. Effects of losartan on blood pressure and left ventricular mass in essential hypertension. Blood Press. 7:1998;75-79.
41. Fogari R., Zoppi A., Mugellini A., et al. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J. 16:1995;1120-1125.
42. Dey H.M., Soufer R., Hoffer P., et al. Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension. Am J Hypertens. 9:1996;598-606.
43. Manolis A.J., Beldekos D., Handanis S., et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic prospensity. Am J Hypertens. 11:1998;640-648.
44. Wambach G., Grimm U., Jacob R. Influence of the cardioselective beta blockers celiprolol and atenolol on 24-h-blood pressure and left ventricular hypertrophy. Nieren-Hochdruckkr. 23:1994;167-169.
45. Beltman F.W., Heesen W.F., Smit A.J., et al. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press. 7:1998;109-117.
46. Cheung B.M.Y., Lau C.-P. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. J Clin Pharmacol. 47:1999;179-187.
47. Galderisi M., Celentano A., Garofalo M., et al. Reduction of left ventricular mass by short term antihypertensive treatment with isradipine a double-blind comparison with enalapril. Int J Clin Pharmacol Ther. 32:1994;312-316.
48. Komsuoglu B., Göldeli Ö., Gacar N., et al. The effects of nitrendipine and verapamil on the index of left ventricular mass in elderly hypertensives with left ventricular hypertrophy. Tr J Med Sci. 21:1994;97-102.
49. De Rosa M.L., Cardace P., Rossi M., et al. Comparative effects of chronic ACE inhibition and angiotensin II receptor blocker losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens. 16:2002;133-140.
50. Malmqvist K., Kahan T., Edner M., et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 19:2001;1167-1176.
51. Devereux R.B., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 194:2001;1248-1254.
52. Schussheim A.E., Diamond J.A., Phillips R.A. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol. 87:2001;61-65.
53. Black H.R., Elliot W.J., Weber M.A., et al. for the Stage 1 Systolic Hypertension (SISH) Study Group. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension. 38:2001;1118-1123.
54. Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients the ELVERA trial. J Hypertens. 19:2001;303-309.
55. Gosse P., Sheridan D.J., Zannad F., et al. on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 18:2000;1465-1475.
56. Heesen W.F., Beltman F.W., Smit A.J., et al. Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. J Cardiovasc Pharmacol. 37:2001;512-521.
57. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomized trial against atenolol. Lancet. 359:2002;995-1003.
58. Nagano M., Higaki J., Mikami H., et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 9:1991;595-599.
59. Schmieder R.E., Langenfeld M.R.W., Friedrich A., et al. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 94:1996;1304-1309.
60. Schlaich M.P., Schobel H.P., Langenfeld M.R.W., et al. Inadequate suppression of Angiotensin II modulates left ventricular structure in humans. Clin Nephrol. 49:1998;153-159.
61. Lubic S.P., Giacomini K.M., Giacomini J.C. The effects of modulation of calcium influx through the voltage sensitive calcium channel on cardiomyocyte hypertrophy. J Mol Cell Cardiol. 27:1995;917-925.
62. Inoue I., Matsuura H., Shingu T., et al. Role of intracellular cation abnormalities in development of left ventricular hypertrophy. J Cardiovasc Pharmacol. 17:(Suppl 2):1991;S107-S109.
63. Rockstroh J.K., Vogt-Ladner G., Neumayer H.H., et al. Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrol Dial Transplant. 12:1997;1441-1447.
64. Chen C.H., Ting C.T., Lin S.J., et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 25:1995;1034-1041.
65. Castellano M., Bohm M. The cardiac beta-adrenoceptor mediated signalling pathway and its alteration in hypertensive heart disease. Hypertension. 29:1997;715-722.